Related Experiment Video
Updated: Aug 19, 2025

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models
Published on: September 27, 2024
Glycogen Synthase Kinase 3β: A True Foe in Pancreatic Cancer
Omer H M Elmadbouh1, Stephen J Pandol1,2, Mouad Edderkaoui1,2
1Department of Medicine, Division of Gastroenterology and Hepatology, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Abstract:
Glycogen synthase kinase 3 beta (GSK-3β) is a serine/threonine protein kinase involved in multiple normal and pathological cell functions, including cell signalling and metabolism. GSK-3β is highly expressed in the onset and progression of multiple cancers with strong involvement in the regulation of proliferation, apoptosis, and chemoresistance. Multiple studies showed pro- and anti-cancer roles of GSK-3β creating confusion about the benefit of targeting GSK-3β for treating cancer. In this mini-review, we focus on the role of GSK-3β in pancreatic cancer. We demonstrate that the proposed anti-cancer roles of GSK-3β are not relevant to pancreatic cancer, and we argue why GSK-3β is, indeed, a very promising therapeutic target in pancreatic cancer.
Insights
Glycogen synthase kinase 3 beta (GSK-3β) plays a key role in pancreatic cancer. Despite conflicting research, GSK-3β is a promising therapeutic target for pancreatic cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Glycogen synthase kinase 3 beta (GSK-3β) is a serine/threonine kinase implicated in diverse cellular functions.
- GSK-3β is frequently overexpressed in various cancers, influencing proliferation, apoptosis, and chemoresistance.
Purpose of the Study:
- To clarify the specific role of GSK-3β in pancreatic cancer progression.
- To evaluate the therapeutic potential of targeting GSK-3β in pancreatic cancer.
Main Methods:
- Review of existing literature on GSK-3β function in cancer.
- Analysis of studies specifically investigating GSK-3β in pancreatic cancer models and patient data.
Main Results:
- Evidence suggests that previously reported anti-cancer roles of GSK-3β are not applicable to pancreatic cancer.
- GSK-3β demonstrates pro-cancer activities in pancreatic cancer, including promoting proliferation and chemoresistance.
Conclusions:
- GSK-3β is a crucial driver of pancreatic cancer.
- Targeting GSK-3β represents a promising therapeutic strategy for pancreatic cancer, contrary to its proposed roles in other cancers.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Cell Specific Gene Expression

